Trellis Bioscience
Latest round
- Series C
Last raised
- Jul 2026
Total raised
- $24M
Investors
- 9
About Trellis Bioscience
Trellis Bioscience, Inc. is a US-based biopharmaceutical company focused on developing monoclonal antibody therapies that target infectious diseases, particularly prosthetic joint infections, respiratory syncytial virus, and human cytomegalovirus. Founded in 2001 and headquartered in Redwood City, US, Trellis Bioscience specializes in monoclonal antibody therapy development. In July 2026, Trellis Bioscience, Inc. The company was founded by Larry Kauvar and Stote Ellsworth, with CEO Stefan Ryser currently at the helm. Trellis Bioscience specializes in developing innovative monoclonal antibody (mAb) therapies targeting infectious diseases. Its lead product, TRL1068 (calpurbatug), is currently in Phase 1 clinical trials. The company utilizes its proprietary CellSpot™ platform for rapid discovery of high-affinity mAbs from human memory B-cells, enhancing therapeutic efficacy. Its product pipeline addresses viral infections caused by HCMV, RSV, and influenza, catering to global health markets. Trellis Bioscience generates revenue primarily through partnerships and collaborations in the biopharmaceutical sector, focusing on clinical studies and the development of monoclonal antibody therapies. The company engages in transactions with pharmaceutical companies and healthcare institutions for research and development initiatives. Revenue is also derived from agreements related to its CellSpot™ technology. Specific pricing details are not disclosed, but transactions align with industry standards, involving clinical development milestones and potential royalties from successful mAb commercialization.
Who invested in Trellis Bioscience
9 investors across 4 rounds
See all investors in Trellis Bioscience
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Questions about Trellis Bioscience
Who invested in Trellis Bioscience?
Trellis Bioscience has 9 investors on record across 4 venture rounds. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has Trellis Bioscience raised?
Trellis Bioscience has raised 4 venture rounds. Sign up free to see how much each round raised and the total.
When did Trellis Bioscience last raise money?
Trellis Bioscience's most recent round on record is a Series C, in Jul 2026.
What does Trellis Bioscience do?
Trellis Bioscience is a biotechnology company.
Where is Trellis Bioscience headquartered?
Trellis Bioscience is headquartered in Redwood City, US.
Which VCs invest in companies like Trellis Bioscience?
Among active investors with capital left to deploy, Andreessen Horowitz, Founders Fund, Accel and Thrive Capital back biotechnology companies at Trellis Bioscience's stage. Their profiles are linked below.
VCs backing biotechnology startups at Series C
Raising like Trellis Bioscience? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.